Radiotheranostics in advanced prostate cancer: Current and future directions

Area of Science:

• Oncology
• Nuclear Medicine
• Radiochemistry

Background:

• Prostate-specific membrane antigen (PSMA) targeted small molecules have revolutionized prostate cancer management.
• PSMA-based agents are crucial for advanced diagnostic imaging and precision radiopharmaceutical therapies.

Purpose of the Study:

• To review current data on PSMA-based imaging in prostate cancer management.
• To discuss ongoing and future clinical trials of PSMA-based radiopharmaceutical therapy (RPT).

Main Methods:

• Literature review of existing data on PSMA-based imaging.
• Analysis of ongoing clinical evaluations and forthcoming trials for PSMA RPT.

Main Results:

• PSMA-based imaging is integral to managing primary, recurrent, and metastatic prostate cancer.
• Clinical studies demonstrate the efficacy of PSMA RPT in metastatic settings, with trials expanding to earlier disease stages.

Conclusions:

• PSMA-targeted agents represent a significant advancement in prostate cancer theranostics.
• Multidisciplinary collaboration is essential for advancing PSMA-based radiotheranostics.